Uncategorized
calendar_month Nov 17, 2026

Novo Nordisk Highlights Protective Bone Biomarkers For CagriSema And Pediatric BMI Drops

Novo Nordisk AG (NYSE:NVO) presented new data at ObesityWeek 2026 demonstrating that its investigational amylin-based therapies support bone health during weight loss, while once-weekly semaglutide significantly reduces body mass index in children with obesity.

Amylin Pipeline Protects Bone Health

Substantial weight loss from medication, surgery, or diet can lower bone mass and increase fracture risks.

On Tuesday, Novo Nordisk shared preclinical and clinical findings showing that dual activation of amylin and calcitonin receptors helps preserve bone integrity.

In an eight-week preclinical study modeling postmenopausal bone loss, cagrilintide and CagriSema curbed trabecular bone deterioration compared with untreated and weight-matched controls.

Femur trabecular bone volume measured 43% higher with cagrilintide and 40% higher with CagriSema, whereas zenagamtide and semaglutide showed smaller, statistically nonsignificant increases. Small clinical studies in healthy volunteers reinforced these findings.

Both cagrilintide and zenagamtide suppressed CTX-I, a bone-breakdown biomarker, while the selective amylin agonist NN1213 did not, indicating that calcitonin receptor activation drives this protective effect.

Post hoc analyses from the phase 3 REDEFINE 1 trial further evaluated CagriSema over 68 weeks.

Although bone mineral density declined alongside substantial weight loss in a 252-participant substudy, levels remained within normal age and sex ranges.

Additionally, CagriSema and cagrilintide elevated the bone-formation marker P1NP and key bone-mineralization blood proteins compared with semaglutide alone, though researchers noted longer follow-up is necessary to assess fracture risk reduction.

Semaglutide Cuts Pediatric Obesity In Phase 3 Trial

On Monday, Novo Nordisk also reported primary results from the phase 3 STEP Young trial, and The New England Journal of Medicine simultaneously published the findings.

The study evaluated once-weekly semaglutide injections alongside diet and exercise in children aged 6 to under 12 with obesity.

At week 68, children receiving semaglutide achieved an estimated mean BMI reduction of 17.4%, compared with a 2.2% increase for placebo under the efficacy estimand.

Furthermore, 40.4% of adherent children on semaglutide no longer met obesity criteria versus 0% on placebo, with safety matching prior trials.

NVO Price Action: Novo Nordisk shares were down 2.94% at $40.37 at the time of publication on Tuesday, according to Benzinga Pro data.

Image via Shutterstock